Showing 4711-4720 of 7372 results for "".
- Dupilumab Reduces Inflammatory Biomarkers in Pediatric AD: Studyhttps://practicaldermatology.com/news/dupilumab-reduces-inflammatory-biomarkers-pediatric-ad/2467953/Dupilumab significantly reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (AD), according to results from recent phase 3 trials. Pediatric patients treated with dupilumab demonstrated substantial reductions in key serum biomarkers associated w
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Higher BMI in Early Childhood Linked with Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/higher-bmi-early-childhood-linked-increased-atopic-dermatitis-risk/2467912/New research indicates that a higher body mass index (BMI) in early childhood is associated with an increased risk of developing immune-mediated skin diseases (IMSDs) such as atopic dermatitis (AD), alopecia areata (AA), and psoriasis. The research team looked at data on over 2 million chi
- Timber Pharmaceuticals Fails Phase 3 Trial for Congenital Ichthyosis Drug Candidatehttps://practicaldermatology.com/news/timber-pharmaceuticals-fails-phase-3-trial-congenital-ichthyosis-drug-candidate/2467911/LEO Pharma's subsidiary, Timber Pharmaceuticals, failed a late-stage trial for its investigational topical ointment formulation of isotretinoin for treating moderate to severe congenital ichthyosis. The phase 3 ASCEND trial was 12-week randomized, double-blind clinical study evaluating TM
- Quitting Smoking Reduces Hidradenitis Suppurativa Riskhttps://practicaldermatology.com/news/quitting-smoking-reduces-hidradenitis-suppurativa-risk/2467901/A new study suggests that smoking cessation is associated with reduced risk of developing hidradenitis suppurativa (HS). Researchers for the population-based cohort study looked at the relationship between the change in smoking habits and the incidence of HS in more than 6 million partic
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- New Plasma Proteins Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/new-plasma-proteins-linked-atopic-dermatitis-risk/2467771/New research has identified eight plasma proteins associated with atopic dermatitis (AD), potentially opening new avenues for treatment. Publishing in the Archives of Dermatological Research, the study authors used summary-data-based Mendelian Randomization (SMR) and evaluated dat
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Annual Science of Skin Event Highlights Empowering Conversations About Chronic Diseaseshttps://practicaldermatology.com/news/annual-science-skin-event-highlights-empowering-conversations-about-chronic-diseases/2467751/Empowering conversations around chronic skin diseases is something AbbVie aims to normalize. The fourth annual Science of Skin event featured a panel of experts and patients who shared insights on managing chronic skin conditions and improving quality of life, and Practical Dermatology was there.
- Tildrakizumab Shows Efficacy in Plaque Psoriasishttps://practicaldermatology.com/news/tildrakizumab-shows-significant-efficacy-plaque-psoriasis/2467713/Tildrakizumab was associated with improvements in disease severity in patients with moderate-to-severe plaque psoriasis, according to results from a new study in the Journal of Drugs in Dermatology. Researchers for the phase 4, multicenter, uncontrolled, open-label trial enrolle